Prevalence and epidemiology of hepatitis B and hepatitis D in Uzbekistan—results from a population-based serosurvey, 2022
Аннотация
Objectives: Uzbekistan, historically a country with high hepatitis B virus (HBV) infection endemicity, introduced infant hepatitis B vaccination in 2001 and has sustained ≥90% coverage for hepatitis B vaccine birth dose (HepB-BD) and three or more doses. In 2017, Uzbekistan initiated hepatitis B elimination activities. However, data on hepatitis B prevalence in the general population were lacking. Methods: In 2022, we conducted a serosurvey among persons aged ≥5 years using stratified cluster sampling. Blood samples were tested for markers of HBV and hepatitis D virus (HDV) infections. Results: < 0.001). Conclusion: Successful hepatitis B vaccination resulted in low HBV infection prevalence among children, but hepatitis B remains widespread among adults in Uzbekistan. Expanding HBV prevention, screening, and treatment among adults, and maintaining high infant vaccination coverage may help achieve hepatitis B elimination in Uzbekistan.
Перевод пока недоступен